SCHEMBL25410662

SCHEMBL25410662

N[C@@H]1C(=O)N2CCCN2Cc2c(F)cccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SPPL2A Q8TCT8 7/20 0.42
▸ AADAT Q8N5Z0 2/20 0.42
▸ MAPK1 P28482 1/20 0.36
▸ HTR2C P28335 1/20 0.34
▸ HTR2B P41595 1/20 0.34
▸ LMNA P02545 2/20 0.32
▸ KDM1A O60341 2/20 0.31
▸ KDM1B Q8NB78 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ DRD2 P14416 1/20 0.31
▸ DRD3 P35462 1/20 0.31
▸ MEN1 O00255 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25407200 1.00 SPPL2A (0.42) SPPL2AAADATMAPK1HTR2CHTR2B
SCHEMBL25409891 0.79 SPPL2A (0.56) SPPL2AAADATLMNA
SCHEMBL25408208 0.79 SPPL2A (0.56) SPPL2AAADATLMNA
SCHEMBL25408832 0.77 ANPEP (0.44) SPPL2AAADAT
SCHEMBL25410229 0.77 ANPEP (0.44) SPPL2AAADAT
SCHEMBL25406983 0.70 TIPARP (0.34) SPPL2AAADATMAPK1LMNAMEN1
SCHEMBL31676052 0.70 AADAT (0.44) SPPL2AAADATHTR2CHTR2BALDH1A1
SCHEMBL30617066 0.68 MAPK1 (0.37) SPPL2AMAPK1HTR2CHTR2BLMNA
SCHEMBL25409042 0.65 HTR2A (0.38) SPPL2AHTR2CHTR2BLMNAKDM1A
Hydrochloric Acid SCHEMBL7500454 0.60 MGLL (0.49) AADATMAPK1KDM1AKDM1BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4578451-A2 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2025-07-02 — — EP disclosed
EP-4214210-B1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS NOVARTIS AG (CH) 2025-04-09 — — EP disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 — — US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 — — US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 — — US disclosed
EP-4214210-A1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2023-07-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS SPPL2A, SPPL2B, BACE1 SPPL2A 1/4885AADAT 3749/4885MAPK1 1689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback